High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.
Glioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes remain poor. First line treatment is well established, however disease invariably recurs and improving prognosis is challenging. With the aim of personalizing therapy at recurrence, we have established a...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Public Library of Science (PLoS)
2018-01-01
|
| سلاسل: | PLoS ONE |
| الوصول للمادة أونلاين: | http://europepmc.org/articles/PMC5834163?pdf=render |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|